Daily therapist-led swallowing exercises cost €124,062 per QALY versus paper guidance in PRESTO

In PRESTO, daily supervised swallowing exercises cost €914 per patient versus €242 for paper guidance, yielding €124,062 per QALY gained.

KEY POINTS

  • This secondary economic analysis of the multicenter, three-arm randomized PRESTO trial evaluated 150 patients with newly diagnosed stage III–IVB oropharyngeal squamous cell carcinoma undergoing radiotherapy or chemoradiotherapy. Patients were assigned to three delivery models for prophylactic swallowing exercises: paper-based self-management, app-based home exercise, or daily therapist-led sessions. All groups performed the same exercise protocol during the first four weeks of oncological treatment.
  • The rehabilitation protocol targeted tongue strength, pharyngeal contraction, laryngeal elevation, and upper esophageal sphincter opening using tongue-strengthening exercises, chin-tuck against resistance, and effortful swallowing. Patients trained five days per week for four weeks. The therapist-led group received 20 face-to-face sessions with a speech-language pathologist (SLP), while the paper and app groups performed exercises independently after initial education. Previously published PRESTO analyses reported adherence rates of 85% with therapist supervision, 69% with paper guidance, and 48% with the app.
  • Therapist-led treatment was substantially more expensive. Total modeled health-system costs were €914.32 per patient for therapist-led care, €533.62 for app-based care, and €242.32 for paper-based self-management. The therapist model therefore cost approximately €672 more per patient than paper guidance. App-based care cost approximately €291 more than paper guidance, mainly because of tablet, connectivity, and application-development expenses, including €242 per patient for app development under the study's cost-allocation assumptions.
  • Generic health-related quality-of-life utility scores did not differ significantly between groups. Mean EQ-5D-5L utility across all participants decreased from 0.79 at baseline to 0.64 after treatment, then recovered to 0.83 at three-month follow-up. Changes over time were significant (p<0.001), but neither the between-group effect (F=0.233; p=0.792) nor the group-by-time interaction (F=0.224; p=0.925) was significant. The absence of a difference in generic utility scores does not establish that swallowing-specific functional outcomes were equivalent.
  • The app-based intervention was economically dominated by paper-based self-management, meaning that it generated comparable measured health benefits at higher cost. Comparing therapist-led versus paper-based care, the mean incremental cost was €672, while the estimated incremental benefit over the three-month evaluation horizon was 0.005417 quality-adjusted life years (QALYs). The resulting incremental cost-effectiveness ratio was €124,061.54 per QALY gained, above the commonly discussed European willingness-to-pay ranges of approximately €20,000–80,000 per QALY.
  • The findings expose an important distinction between exercise adherence, swallowing-specific outcomes, and generic quality-of-life utility. Earlier PRESTO analyses found that adherence exceeding 75% was associated with better tongue strength and swallowing function, favoring intensive professional involvement. However, the present economic evaluation relied on EQ-5D-5L, which may be insufficiently sensitive to dysphagia-related changes. Therefore, failure to demonstrate cost-effectiveness in generic QALYs does not mean that supervised rehabilitation lacks functional benefit.
  • Generalizability is limited by the short three-month economic horizon, Belgian staffing and reimbursement assumptions, and the relatively high intensity of the therapist-led regimen. Application-development expenses were allocated across a small trial population and could be substantially different in larger-scale deployment. The analysis also did not comprehensively account for lost productivity, long-term swallowing complications, or downstream healthcare costs. Hybrid models involving intermittent SLP supervision with home-based exercises were not tested, leaving the minimum cost-effective level of professional involvement unresolved.

CLINICAL TAKEAWAY

Daily therapist-supervised prophylactic swallowing exercises improved adherence in PRESTO but did not demonstrate sufficient additional generic quality-of-life benefit to justify their substantially higher costs over the short evaluation period. For patients undergoing head and neck chemoradiotherapy, the findings support exploring lower-cost or hybrid rehabilitation models that preserve clinically meaningful swallowing outcomes while reducing intensive therapist contact, rather than abandoning prophylactic swallowing therapy.

SOURCE

Head & Neck

Browse more research Suggest a correction